Feature|Podcasts|September 23, 2024
A Different Approach to Dermatology Care
Author(s)Miranda Schmalfuhs
Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.
Advertisement
Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses:
- How they're positioning the company to capitalize on the unmet needs in other specific therapeutic areas
- Strategies to ensure long-term success in these spaces
- Patient centric initiatives they've implemented to ensure the patient voice is integrated into drug development and commercialization processes
- Their approach to orphan drug development
- Challenges and opportunities adapting to the US market
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments
2
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
How Can AI Life Sciences Companies Stand Out at the Upcoming JP Morgan Healthcare Conference?
5